SC
AMRX icon

Stephens Consulting’s Amneal Pharmaceuticals AMRX Stock Holding History

Stephens Consulting’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45
Closed -$378 – 1232
2025
Q1 		$378 Buy
+45
New +$376 ﹤0.01% 1143

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stephens Consulting's AMRX Position: Q2 2025 in Review

Stephens Consulting sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 45 shares — an estimated $378 sold.

Stephens Consulting first reported a position in AMRX in Q1 2025 and held it in 1 quarter. The position peaked at $378 in Q1 2025. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

  • Stephens Consulting reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 45 Amneal Pharmaceuticals shares in Q2 2025, an estimated $378.
  • Stephens Consulting first reported a position in Amneal Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Amneal Pharmaceuticals position peaked at $378 in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.